ABSTRACT
Malignant salivary gland tumors are relatively rare and account for only 3%-4% of all head and neck cancers. Especially in adenoid cystic carcinoma, the incidence of local recurrence and distant metastases is influenced by the perineural spread of tumor. In advanced salivary gland tumors, surgery alone has a high incidence of local failure. The results of conventional radiotherapy are suboptimal in inoperable or not completely resected salivary gland tumors and in recurrent disease. The pooled data of some international series for low linear energy transfer radiation show a local control of only 28%. Especially in advanced salivary gland tumors, neutron therapy can improve local control. In Europe at least 570 patients with salivary gland tumors have been treated with neutrons alone or with combined modalities. The clinical data of different centers in Europe and the United States result in a similar local control rate of 67% in gross disease. An analysis of different European series shows on average a complication rate of 10.6% for severe radiation-related morbidity. Modern neutron machines and the use of three-dimensional treatment planning systems are now available in a few institutions and may further reduce side effects.
Subject(s)
Neutrons/therapeutic use , Salivary Gland Neoplasms/radiotherapy , Aged , Humans , Salivary Gland Neoplasms/mortality , Survival RateABSTRACT
In Europe to date, 501 patients with salivary gland tumors have been treated with neutrons alone or with combined modalities. The most common histological types are adenoid cystic carcinomas, mucoepidermoid carcinomas and malignant mixed tumors. The results of conventional radiotherapy are suboptimal in inoperable or incompletely resected salivary gland tumors and in recurrent disease. The pooled data of some international series for low linear energy transfer radiation show a local control of 28%. Especially in advanced tumors neutron therapy can improve local control and should be the treatment of choice. The clinical data from different therapy centers in Europe show local control of 67% in gross disease.
Subject(s)
Carcinoma, Adenoid Cystic/radiotherapy , Carcinoma, Mucoepidermoid/radiotherapy , Fast Neutrons , Radiotherapy, High-Energy/methods , Salivary Gland Neoplasms/radiotherapy , Carcinoma, Adenoid Cystic/mortality , Carcinoma, Adenoid Cystic/pathology , Carcinoma, Mucoepidermoid/mortality , Carcinoma, Mucoepidermoid/pathology , Combined Modality Therapy , Europe , Follow-Up Studies , Humans , Neoplasm Staging , Prognosis , Radiotherapy Dosage , Salivary Gland Neoplasms/mortality , Salivary Gland Neoplasms/pathology , Survival AnalysisSubject(s)
Bacterial Infections/drug therapy , Ofloxacin/therapeutic use , Prostatitis/drug therapy , Adult , Anti-Infective Agents/therapeutic use , Clinical Trials as Topic , Escherichia coli Infections/drug therapy , Gram-Positive Bacterial Infections/drug therapy , Humans , Leukocyte Count , Male , Pseudomonas Infections/drug therapyABSTRACT
In an open study, 22 patients with genito-urinary infection by Chlamydia trachomatis were treated with oral fleroxacin in varying dosage. Symptoms were relieved and cultures became negative in 19 patients, with three patients not assessable. Adverse reactions, affecting the central nervous system, the gastrointestinal tract and the skin (photosensitivity), were reported in seven patients.
